Bioequivalence of Single Dose Phenylephrine Extended Release Tablets and Phenylephrine HCl Immediate Release Tablets Dosed Every Four Hours (P08340)(COMPLETED)

Inclusion Criteria: * In good health * Female participants must not be pregnant * Agrees to use two acceptable methods of birth control throughout the study * Agrees not to take monoamine oxidase inhibitor (MAOI) for 2 weeks prior to, during, and 2 weeks after the end of the study Exclusion Criteria: * Any significant medical condition which is a contraindication to the use of phenylephrine HCl, might interfere with the study, or requires treatment expected to affect blood pressure * Any infectious disease within 4 weeks prior to initial treatment administration * History of malignancy, except basal cell carcinoma * Cannot comply with requirement to abstain from the use of any drugs (except acetaminophen or herbal/vitamin supplements) within 14 days prior to study and alcohol or xanthine-containing substances (coffee, chocolate) within 72 hours prior to study * Received an investigational drug within thirty days prior to study drug dosing * Known or apparent current or former drug addicts or alcoholics * Positive for Human Immunodeficiency Virus (HIV) antibody, hepatitis B surface antigen, or hepatitis C antibody * Cannot accept a high-fat, high-calorie breakfast * Known allergy or intolerance to phenylephrine HCl * Have used phenylephrine-containing product within 2 weeks prior to study start * Have smoked tobacco, used tobacco products, or used a nicotine-containing smoking cessation aid within the past 6 months